This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ammarguellat, F. Z. Articles by Schiffrin, E. L. Search for Related Content PubMed PubMed Citation Articles by Ammarguellat, F. Z. Articles by Schiffrin, E. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Diseases High Blood Pressure Related Collections Other myocardial biology Remodeling Other hypertension Hypertension - basic studies Hypertrophy Endothelium/vascular type/nitric oxide

(Hypertension. 2002;39:679.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Fibrosis, Matrix Metalloproteinases, and Inflammation in the Heart of DOCA-Salt Hypertensive Rats: Role of ET_A Receptors

Fatima Z. Ammarguellat; Philippe O. Gannon; Farhad Amiri; Ernesto L. Schiffrin

From the Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, Quebec, Canada.

Correspondence to Ernesto L. Schiffrin, MD, PhD, FRCPC, Clinical Research Institute of Montreal, 110, Avenue des Pins Ouest, Montréal, Québec, Canada H2W 1R7. E-mail schiffe{at}IRCM.qc.ca

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
In deoxycorticosterone acetate (DOCA)-salt hypertension, the endothelin-1 system is activated and plays a role in cardiac fibrosis. Remodeling of extracellular matrix (ECM) may lead to interstitial fibrosis, which may contribute to heart failure. Imbalance in synthesis and degradation of the ECM by matrix metalloproteinases (MMPs) as well as inflammation may play a role in matrix protein deposition and cardiac remodeling in hypertension. We measured expression of the extracellular matrix protein fibronectin, the activity of the gelatinases MMP-2 and MMP-9, the proinflammatory transcription factor NFB, and the adhesion molecules, vascular cell adhesion molecule (VCAM)-1 and platelet-endothelial cell adhesion molecule (PECAM)-1 in hearts of DOCA-salt hypertensive (DS) rats treated or not with the endothelin ET_A antagonist BMS 182874 (BMS). Unilaterally nephrectomized rats (UniNx) were compared with DS rats treated or not with BMS 40 mg/kg/d. Fibronectin deposition was detectable at the first week, and remained elevated thereafter. This increase was abrogated by administration of the ET_A antagonist. Enzymatic activity of gelatinases was increased (P<0.01) in DS compared with control during the first and second week. BMS blocked the increase of MMP-2 and MMP-9 activity at week 1 (P<0.05); MMP activity remained lower than in DS at week 2. NF-B binding activity in DS was higher (P<0.05) than it was in controls during the second week, and was reduced by BMS. The adhesion molecules VCAM-1 and PECAM-1, and the antiapoptotic molecule xIAP were upregulated in the left ventricle of the heart of DS rats and downregulated in the rats treated with the ET_A antagonist. In conclusion, cardiac extracellular remodeling in rats with endothelin-dependent hypertension was associated with increased fibronectin, MMP activity, and upregulation of inflammatory mediators, all of which were reduced by ET_A antagonism.

Key Words: hypertension, mineralocorticoid • myocardium • endothelin • fibronectin • apoptosis

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
A number of studies have demonstrated that there is an endothelin (ET)-dependent component in blood pressure elevation and in vascular, cardiac, and renal complications in mineralocorticoid hypertension, including that in the deoxycorticosterone acetate (DOCA)-salt hypertensive rat.^1–5 We previously showed that collagen deposition was dramatically increased in the left ventricle of DOCA-salt rats.³ Although development of left ventricular hypertrophy was unaffected by treatment with the ET_A-selective endothelin receptor antagonist A-127722, cardiac collagen deposition was significantly reduced. Collagen deposition was associated with increased transforming growth factor (TGF)ß₁ expression, a well-known profibrotic factor, which was also abrogated by the ET_A antagonist. Collagen deposition is not the only mechanism involved in remodeling of the heart in hypertension and under the action of hormones such as ET-1, angiotensin II, and aldosterone. Matrix metalloproteinase (MMP) expression is increased in the heart in experimental animals and in patients with heart failure.^6,7 Indeed, MMPs have a major role in extracellular matrix (ECM) protein turnover.⁸ The enzymes capable of degrading fibrillar helices are interstitial collagenases or MMP-1 and MMP-8. The resulting fragments unfold their triple helix conformation. So-formed single alpha-chains (gelatins) can be further degraded into oligopeptides by less specific proteinases such as gelatinases (72 kDa MMP-2 and 92 kDa MMP-9).⁹

During inflammatory responses, one of the mediators that is activated is the nuclear factor NF-B, which activates numerous genes that include adhesion molecules involved in recruitment of circulating leukocytes to sites of inflammation. Among these adhesion molecules are intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1).^10,11 Other mechanisms including apoptosis may be activated during inflammatory response in tissues such as the heart. Apoptosis has been documented both in the myocardium in a number of clinically important states, including hypoxia¹² and myocardial infarction,¹³ and in the hearts of patients with end-stage heart failure.^14,15 Cellular factors including NF-B have been shown to interact with key antiapoptotic genes such as Bcl-2¹⁶ and inhibitor of apoptosis proteins (IAPs).^17,18

In this study we asked the following questions: Is fibronectin increased together with collagen in the left ventricle of DOCA-salt hypertensive rats, and, if so, is this increase dependent on ET_A receptor activation? Will this be associated with ET_A-dependent upregulation of MMP activity, and increased expression of mediators of inflammation like NF-B and adhesion molecules such as ICAM-1, VCAM-1, and platelet-endothelial cell adhesion molecule-1 (PECAM-1) in the heart? Because apoptosis may be activated in cardiovascular tissues in DOCA-salt hypertensive rats,¹⁹ we proposed that there would be a reactive (compensatory) increase in xIAP expression in the left ventricle of these rats.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials
The antibody against fibronectin was from Calbiochem-Novachem Corporation. Antibodies against VCAM-1, ICAM-1, PECAM-1, and p65 subunit of NF-B, as well as the secondary antibodies, anti-rabbit, anti-mouse, and anti-goat were bought from Santa-Cruz. The anti-xIAP was from Transduction Laboratories. The oligonucleotide containing the NF-B binding site was from Promega Corporation. Oregon Green 488 conjugated-gelatin was bought from Molecular Probes Inc. Other products were from Sigma Chemical Co unless specified.

Animal Experiments
The study was approved by the Animal Care Committee of the Clinical Research Institute of Montreal and conducted in accordance with recommendations of the Canadian Council of Animal Care. DOCA-salt hypertension was induced by the method of Ormsbee and Ryan.²⁰ Male Sprague-Dawley rats (Charles River, St. Constant, QC, Canada) weighing 200 g were unilaterally nephrectomized under ketamine anesthesia (50 mg/kg)-xylazine (5 mg/kg). Silicone rubber impregnated with DOCA (Sigma Chemical Co) (200 mg per rat) was implanted subcutaneously, and rats were offered 1% saline to drink. Control rats (UniNx) were also unilaterally nephrectomized but received a silicone rubber implant without DOCA and tap water to drink. The ET_A endothelin receptor antagonist, BMS182874 (BMS), was administered to DOCA-salt rats in the drinking water (40 mg/kg/d) for 1, 2, or 4 weeks. After warming the rats, systolic blood pressure (BP) was measured weekly by the tail-cuff method while rats were under slight restraint. Readings were recorded on a model 7 polygraph fitted with a 7-P8 preamplifier and PCPB photoelectric pulse sensor (all from Grass Instruments Co); on average, 3 pressure readings were obtained. Rats were euthanized by decapitation at the end of the experiment; part of the heart was frozen at -80°C for protein analysis, and another part was dipped in Tissue-Tek optimum cutting temperature compound 4583 (OCT compound, Sakura Finetek USA Inc) and frozen at -80°C.

In Situ Zymography
Fresh frozen sections (5 µm) were incubated with 0.5 mg/mL gelatin-Oregon Green in developing buffer, pH 7.4 (Tris Base) 50 mmol/L, HCl 40 mmol/L, NaCl 200 mmol/L, CaCl₂-2H₂0 5 mmol/L, Brij 35 (wt/vol) 0.29, phenylmethylsulfonylfluoride (PMSF) 50 mmol/L, at 37°C for 3 hours. Slides were washed 3 times with PBS pH 7.4 to remove unbound gelatin. Gelatinase activity resulted in the loss of quenching; therefore an increase in activity was visualized as a linear increase in fluorescence. The presence of PMSF in the developing buffer ensures increased fluorescence was not due to a serine protease. Also, because MMP activity depends on the presence of calcium, this requirement for lytic activity was assessed with the addition of 50 mmol/L ethylenediaminetetraacetic acid (EDTA) in the developing buffer. Co-DNA staining has been performed with the fluorescent dye DAPI (4',6-diamidine-2'-phenylindole dihydrochloride) from Molecular Probes. Heart sections were incubated with 1 µg/mL DAPI in methanol for 30 minutes at 37°C and then washed 3 times with PBS, pH 7.4. A microscope equipped with a mercury lamp and epifluorescence optics was used to visualize fluorescence. The green fluorescence was quantified as percent area of fluorescence over total area, using an image analysis system (Northern Eclipse 5.0, EMPIX Imaging Inc).

Western Blot Analysis
Protein was extracted from frozen tissue in lysis buffer containing PBS (pH 7.4), 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L sodium orthovanadate, 1 mmol/L PMSF, 1% NonidetP-40, and aprotinin, leupeptin, and pepstatin (1 µg/mL each). Protein concentration was determined using the BioRad protein assay (Bio-Rad Laboratories Inc). Samples were electrophoresed in reduced conditions in a 10% SDS-polyacrylamide gel at 60 V for 2 hours and transferred to a polyvinylidine difluoride membrane at 100 V for 1 hour. Membranes were incubated overnight at 4°C, with the specific antibodies at dilutions indicated in the Table. Horseradish peroxidase-conjugated IgG was used as second antibody for 1 hour at room temperature. Bands were visualized by chemiluminescence kit (Roche Molecular Biochemicals) and quantified by densitometry.

View this table: [in this window] [in a new window]   Table 1. Dilutions of Specific Antibodies

Electrophoretic Mobility Shift Assay for Measurement of NF-B Activity
Nuclear protein was extracted as described previously.²¹ Briefly, frozen tissues were homogenized and resuspended in 1 mL 50 mmol/L Tris (pH 7.4) containing 1 mmol/L orthovanadate, 1 µg/µL pepstatin, and 1 µg/µL aprotinin. The suspension was centrifuged at 2500g for 4 minutes at 4°C. The pellet was resuspended in 1 mL lysis buffer containing 20 mmol/L HEPES (pH 7.9), 350 mmol/L NaCl, 20% glycerol, 1 mmol/L MgCl₂, 0.5 mmol/L EDTA, 0.1 mmol/L EGTA, 1% Nonidet P-40) containing protease inhibitors (pepstatin [1 µg/µL], aprotinin [1 µg/µL], leupeptin [1 µg/µL], PMSF [1 mmol/L], orthovanadate [1 mmol/L]), incubated on ice for 30 minutes, and centrifuged at 16 200g for 10 minutes at 4°C. The supernatant was aliquoted and frozen at -80°C until use. Protein concentration was assessed by BioRad reagent. Twenty micrograms of nuclear protein were incubated in 1x gel shift binding buffer (50 mmol/L Tris, 250 mmol/L NaCl, 20% glycerol, 2.5 mmol/L EDTA, 2.5 mmol/l DTT, 5 mmol/L MgCl₂, 0.25 mg/mL poly dI:dC) with 0.5 ng of ³²P-dATP end-labeled double-stranded oligonucleotide containing the NF-B (5'-AGTTGAGGG-GACTTTCCCAGGC-3') binding site for 30 minutes at room temperature. In competition assays, 50 ng of unlabeled oligonucleotide was used whereas supershift assays used an anti-p65 antibody that does not interfere with the oligonucleotide-protein binding site. The DNA-protein complexes were analyzed on a 4% polyacrylamide gel in 0.5x Tris-borate-EDTA buffer, dried, and autoradiographed.

Analysis of Data
Results were analyzed by ANOVA and a Newman-Keuls post hoc test and were considered statistically significant if P<0.05.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
BP rose with DOCA-salt treatment to 225±9.4 mm Hg compared with control (112±2.6 mm Hg, P<0.01). BP of DOCA-salt rats treated was significantly lower with the ET_A selective antagonist BMS (137±3.4 mm Hg, P<0.01 versus DOCA-salt), similar to what we previously reported with other ET_A selective antagonists.³ In that report,³ increased deposition of collagen in the left ventricle of the heart was also shown to occur throughout the period studied. Here we show that, in all times studied (1, 2, and 4 weeks), the DOCA-salt rat left ventricle exhibited significant increases in fibronectin expression (Figure 1), which were abrogated by treatment with ET_A antagonist.

View larger version (21K): [in this window] [in a new window]   Figure 1. Fibronectin expression in left ventricle of DOCA-salt hypertensive rats and effect of ETA antagonism. Results are means±SEM (n=3). *P<0.05, P<0.01 versus other groups. UniNx=unilaterally nephrectomized controls, ETAA=ETA receptor antagonist. Top panel shows representative Western blot of results at 1 week.

Gelatinase activity (probably representing activity of MMP-2 and MMP-9) was examined by in situ zymography (Figure 2). Gelatinase activity was inhibited by the metal chelator EDTA, but not by the serine protease inhibitor PMSF, which confirmed that lysis of gelatin was due to MMP activity. The top of Figure 2 shows representative gelatinase activity on heart sections of control, DOCA-salt, and ET_A antagonist-treated rats. Gelatinase activity was significantly increased in hearts of DOCA-salt rats at 1, 2, and 4 weeks, compared with the other 2 groups (Figure 2, bottom), and reduced by ET_A antagonist treatment.

View larger version (68K): [in this window] [in a new window]   Figure 2. Top, In situ zymography to evaluate gelatinase activity on sections of left ventricle. A, Oregon Green 488 conjugated-gelatin. B, Costaining with DAPI to show nuclei. C, Disappearance of lysis with EDTA confirmed that lysis was due to MMPs and not a serine protease. Bottom, Quantification of fluorescence from degraded gelatin. Results are means±SEM (n=3). * P<0.05 versus DOCA-salt+ETA antagonist, P<0.01 versus UniNx control.

NF-B binding was studied by EMSA and specificity demonstrated by supershift with antibody against NF-B p65 subunit and by competition with excess unlabeled specific NF-B binding oligonucleotides (Figure 3). Bottom panels of Figure 3 show that NF-B DNA binding was increased in DOCA-salt rat hearts compared with control during the second week (P<0.05), and tended to remain elevated on the fourth week (not achieving significance, however). Treatment with the ET_A antagonist reduced NF-B activity.

View larger version (73K): [in this window] [in a new window]   Figure 3. Top, NF-B binding activity in left ventricle. Binding specificity was assessed by supershift with anti-NF-B p65 subunit antibody and by competition with excess unlabeled NF-B binding oligonucleotides. Bottom, NF-B binding activity in the heart of control, DOCA-salt, and ETA antagonist-treated rats. Results are means±SEM (n=5). * P<0.05 versus other groups.

VCAM-1 expression (Figure 4A) was significantly increased in hearts of DOCA-salt rats at week 1 (P<0.01 versus control), and week 2 (P<0.05 versus control), and was decreased by the ET_A antagonist (P<0.01 during week 1, P<0.05 at week 2). At week 4, VCAM-1 expression was not significantly different between groups. ICAM-1 expression was similar in all groups (not shown). PECAM-1 expression (Figure 4B) was increased in hearts of DOCA-salt rats from week 1 to 4 (P<0.05 versus control group). PECAM-1 expression in heart was significantly decreased by the ET_A antagonist at week 1 and 4 (P<0.05), and at week 2 there was a trend to decrease, which did not reach statistical significance, in the treated group.

View larger version (39K): [in this window] [in a new window]   Figure 4. A, Expression of VCAM-1 (110 kDa) in left ventricle. Results are means±SEM (n=3). * P<0.05, P<0.01 versus other groups. Top panels show a representative Western blot. B, Expression of PECAM-1 (140 kDa) in left ventricle. Results are means±SEM (n=3). * P<0.05 versus other groups, P<0.05 versus UniNx. Top panels show representative Western blots.

xIAP expression was 1.6-fold higher in hearts of DOCA-salt rats after the first week (Figure 5). This response was abrogated in rats treated with the ET_A antagonist. No significant differences between groups were observed at weeks 2 and 4.

View larger version (18K): [in this window] [in a new window]   Figure 5. Expression of xIAP (57 kDa) in left ventricle. Results are means±SEM (n=3). *P<0.05 versus other groups. Top panels show representative Western blots.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The present study demonstrates molecular events associated with fibrosis and remodeling in the heart of rats with DOCA-salt hypertension. In this model of mineralocorticoid hypertension, activation of inflammatory mediators and matrix metalloproteinases as well as antiapoptotic molecules could be major components of cardiac remodeling in response to salt and mineralocorticoids, and could play a critical role leading to cardiac fibrosis.³ Since cardiac fibrosis that occurs in response to salt and mineralocorticoids is mediated at least partly by ET-1,³ we hypothesized that ET_A receptor antagonism would abrogate these pathophysiologic responses. Our results demonstrate that inflammatory mediators (NF-B), adhesion molecules VCAM-1 and PECAM-1, MMPs, and the antiapoptotic molecule xIAP are upregulated in the heart of DOCA-salt rats, and that this can be prevented by an ET_A receptor antagonist. The mechanisms whereby mineralocorticoids together with salt may upregulate the endothelin system^1–5 remain elusive; the possible role of vasopressin has been suggested.^22,23 Mineralocorticoids could potentiate the action of vasopressin on ET-1 expression in the heart, or alternatively, mineralocorticoids could directly or indirectly stimulate vasopressin secretion, which could in turn stimulate ET-1 expression.^22,23

Collagen deposition, such as that we documented in hearts of DOCA-salt rats,⁴ and more recently in rats treated with aldosterone and salt,⁵ has a particular time-course, with increase in procollagen I mRNA expression found early, and procollagen III mRNA expression significantly different only at week 4. The collagen III/collagen I ratio could play an important role in raising cardiac stiffness, because a lower ratio results in a stiffer, less compliant ventricle. Here we showed that fibronectin, another fibrillar component of extracellular matrix with influence on mechanical properties of tissues, is increased early on in the left ventricle of DOCA-salt rats, and that this increase was prevented by the ET_A antagonist. Fibronectin is a glycoprotein that forms a bridge between cells and the interstitial collagen network. The early and sustained increase of fibronectin deposition in the heart could precede collagen I deposition and contribute to extracellular-cell attachment remodeling on which collagen deposition becomes embedded.

Breakdown of mature extracellular matrix proteins involves many MMPs and interplay with their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Increased gelatinase activity in hearts of DOCA-salt hypertensive rats may be part of the remodeling process of the extracellular matrix that contributes to distortion of cardiomyocyte architecture and organization. New collagen and fibronectin deposition may contribute to worsening of cardiac stiffness and contractility. The reversal of gelatinase activity by ET_A antagonism may contribute to prevent cardiac remodeling. Inhibition of ET_A receptors prevented MMP activation in postmyocardial infarction in the rat.²⁴ The authors speculated that ET_A antagonists may act on cardiac fibroblasts. Increased gelatinase activity in DOCA-salt heart sections could be due to MMP-2, which, unlike MMP-9, is synthesized by many cell types including fibroblasts, and may be stimulated by TGFß₁.⁸ TGFß₁ expression in the left ventricle increases early in DOCA-salt hypertension.³ TGFß₁ may play a role in extracellular matrix remodeling by stimulating collagen synthesis and increasing turnover and degradation of collagen.

NF-B, increased by an ET_A-dependent pathway in the present experimental paradigm, regulates expression of genes involved in immune, inflammatory, and growth responses.^25,26 Inflammatory changes induced by L-NAME may be abrogated by a NF-B decoy strategy.²⁷ However, NF-B decoy oligodeoxynucleotides were unable to reduce gene expression of TGFß₁ as well as perivascular and cardiac fibrosis. NF-B activation may result from increased oxidative stress,²⁸ which may be induced by ET-1. A recent study showed reactive oxygen species-dependent NF-B activation in kidney of mineralocorticoid hypertensive rats.²⁹ ET-1 may activate profibrotic factors and cardiac fibrosis through different pathways, involving TGFß₁ on the one hand and inflammatory changes through NF-B on the other. Several TGF-ß₁-responsive promoters have been identified, including fibronectin³⁰ and collagen I promoters .^31,32 This may underlie the finding that, whereas collagen and fibronectin are already upregulated at 1 week, NF-B binding activity rose only at 2 weeks of DOCA-salt treatment.

The endothelium becomes dysfunctional in the early stages of vascular diseases, and this involves, among other molecular and cellular processes, an inflammatory component³³ mediated by adhesion molecules, targets of NF-B. Transcriptional activation of those genes is tightly regulated by NF-B.³⁴ In the present study, VCAM-1 and PECAM-1 expression were increased in ET_A receptor-dependent fashion in DOCA-salt hypertensive rats, whereas ICAM-1 appeared unaffected. Upregulation of these adhesion molecules may not be simultaneous. In a model of experimental colitis in which VCAM-1 played a central role in leukocyte recruitment, immunoneutralization of ICAM-1 had no therapeutic effect.³⁵ Interestingly, adhesion molecule upregulation occurred at a time when NF-B upregulation could not be detected.

NF-B may be a ubiquitous multifunctional signaling system that contributes to cell survival.^36,37 It may also be proapoptotic in some cell types.³⁸ We previously reported that the activation of apoptosis in cardiovascular tissues of DOCA-salt hypertensive rats may fine-tune cardiovascular growth.¹⁹ For this reason we examined the expression of the inhibitor of apoptosis xIAP^17,18 and found it enhanced at an early stage in DOCA-salt rats, which resembles what we previously described for TGFß₁.³ xIAP has recently been demonstrated to function as a cofactor of TGFß₁.³⁹ xIAP may thus potentiate TGFß₁-induced signaling. xIAP may also be involved in the activation of transcriptional mediators of TGF-ß₁ signaling.⁴⁰

In the present study, as in previous ones, ET_A antagonism was associated with moderate BP reduction in DOCA-salt hypertensive rats. Whether BP reduction may contribute to the present findings is not clarified by this study. Although the development of cardiac fibrosis and left ventricular hypertrophy concomitant with blood pressure rise in the DOCA-salt model may indicate a role for blood pressure elevation, cardiac fibrosis occurs in both ventricles whereas atrial natriuretic peptide gene expression is stimulated only in the left but not the right ventricle, and prevention of cardiac fibrosis by subhypotensive doses of spironolactone⁴¹ support a blood pressure-independent effect of mineralocorticoids in the induction of cardiac fibrosis. In this model cardiac fibrosis affects both the right and the left ventricle, which is more typically a hormonal than a hemodynamic effect. Thus, in contrast to cardiac hypertrophy that can be attributed to BP elevation, cardiac fibrosis and inflammation may be attributed to mineralocorticoid action.⁴¹

In conclusion, these findings together with previous data suggest that in the early phase of fibrosis in the heart of DOCA-salt hypertensive rats, ET-1, via the ET_A receptor, activates TGFß₁, NF-B activity, and xIAP expression. Inflammation in response to upregulation of NF-B activity is associated with increased PECAM-1 and VCAM-1. Antagonism of ET_A receptors may provide a new therapeutic strategy for targeting hormonally mediated changes occurring in the heart in some forms of cardiovascular disease with increased mineralocorticoid activity, in order to prevent inflammation, fibrosis, and extracellular matrix remodeling.

	Acknowledgments

 
This work was supported by grant 37917 and a group grant to the Multidisciplinary Research Group on Hypertension, both from the Canadian Institutes of Health Research. Farhad Amiri was supported by a summer studentship from the Canadian Hypertension Society.

Received September 22, 2001; first decision November 12, 2001; accepted November 26, 2001.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993; 21: 294–300.[Abstract/Free Full Text]
2. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994; 24: 183–188.[Abstract/Free Full Text]
3. Ammarguellat F, Larouche II, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation. 2001; 103: 319–324.[Abstract/Free Full Text]
4. Park JB, Schiffrin EL. ET_A receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001; 37: 1444–1449.[Abstract/Free Full Text]
5. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens. 2001; in press.
6. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res. 2000; 46: 307–315.[Abstract/Free Full Text]
7. Cleutjens JP. The role of matrix metalloproteinases in heart disease. Cardiovasc Res. 1996; 32: 816–821.[CrossRef][Medline] [Order article via Infotrieve]
8. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5 (8): 2145–2154.[Abstract]
9. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000; 14: 2123–2133.[Free Full Text]
10. Tomita N, Morishita R, Tomita S, Kaneda Y, Higaki J, Ogihara T, Horiuchi M. Inhibition of TNF-alpha, Induced Cytokine and Adhesion Molecule expression in glomerular cells in vitro and in vivo by transcription factor decoy for NF-kappab. Exp Nephrol. 2001; 9: 181–190.[CrossRef][Medline] [Order article via Infotrieve]
11. Iwata A, Sai S, Moore M, Nyhuis J, Fries-Hallstrand R, Quetingco GC, Allen MD. Gene therapy of transplant arteriopathy by liposome-mediated transfection of endothelial nitric oxide synthase. J Heart Lung Transplant. 2000; 19: 1017–1028.[CrossRef][Medline] [Order article via Infotrieve]
12. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 1994; 75: 426–433.[Abstract/Free Full Text]
13. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest. 1996; 74: 86–107.[Medline] [Order article via Infotrieve]
14. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996; 335: 1182–1189.[Abstract/Free Full Text]
15. Quaini F, Cigola E, Lagrasta C, Saccani G, Quaini E, Rossi C, Olivetti G, Anversa P. End-stage cardiac failure in humans is coupled with the induction of proliferating cell nuclear antigen and nuclear mitotic division in ventricular myocytes. Circ Res. 1994; 75: 1050–1063.[Abstract/Free Full Text]
16. Kirshenbaum LA. Bcl-2 intersects the NFkappaB signalling pathway and suppresses apoptosis in ventricular myocytes. Clin Invest Med. 2000; 23: 322–330.[Medline] [Order article via Infotrieve]
17. Levkau B, Garton KJ, Ferri N, Kloke K, Nofer JR, Baba HA, Raines EW, Breithardt G. xIAP induces cell-cycle arrest and activates nuclear factor-kappaB: new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res. 2001; 88: 282–290.[Abstract/Free Full Text]
18. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked IAP gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med. 1998; 188: 211–216.[Abstract/Free Full Text]
19. Sharifi AM, Schiffrin EL. Apoptosis in aorta of DOCA-salt hypertensive rats: effect of endothelin receptor antagonism. J Hypertens. 1997; 15: 1441–1448.[CrossRef][Medline] [Order article via Infotrieve]
20. Ormsbee HSIII, Ryan CF. Production of hypertension with desoxycorticorticosterone acetate-impregnated silicone rubber implants. J Pharm Sci. 1973; 62: 255–257.[CrossRef][Medline] [Order article via Infotrieve]
21. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000; 35: 193–201.[Abstract/Free Full Text]
22. Intengan HD, He G, Schiffrin EL. Effect of V₁ vasopressin antagonism on small artery structure and vascular expression of preproendothelin-1 in DOCA-salt hypertensive rats. Hypertension. 1998; 32: 770–777.[Abstract/Free Full Text]
23. Intengan HD, Park J-B, Schiffrin EL. Blood pressure, resistance artery structure and mechanics in DOCA-salt-treated vasopressin-deficient Brattleboro rats Role of endothelin. Hypertension. 1999; 34: 907–913.[Abstract/Free Full Text]
24. Podesser BK, Siwik DA, Eberli FR, Sam F, Ngoy S, Lambert J, Ngo K, Apstein CS, Colucci WS. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol. 2001; 280: H984–H991.[Abstract/Free Full Text]
25. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336: 1066–1071.[Free Full Text]
26. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell. 1995; 80: 529–532.[CrossRef][Medline] [Order article via Infotrieve]
27. Kitamoto S, Egashira K, Kataoka C, Koyanagi M, Katoh M, Shimokawa H, Morishita R, Kaneda Y, Sueishi K, Takeshita A. Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats. Circulation. 2000; 102: 806–812.[Abstract/Free Full Text]
28. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep. 2000; 2: 98–105.[Medline] [Order article via Infotrieve]
29. Beswick RA, Zhang HF, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension. 2001; 37: 781–786.[Abstract/Free Full Text]
30. Hocevar BA, Brown TL, Howe PH. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 1999; 18: 1345–1356.[CrossRef][Medline] [Order article via Infotrieve]
31. Chung KY, Agarwal A, Uitto J, Mauviel A. An AP-1 binding sequence is essential for regulation of the human alpha2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem. 1996; 271: 3272–3278.[Abstract/Free Full Text]
32. Vindevoghel L, Kon A, Lechleider RJ, Uitto J, Roberts AB, Mauviel A. Smad-dependent transcriptional activation of human type VII collagen gene (COL7A1) promoter by transforming growth factor-beta. J Biol Chem. 1998; 273: 13053–13057.[Abstract/Free Full Text]
33. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.[Free Full Text]
34. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol. 1997; 82: 297–304.[Abstract]
35. Soriano A, Salas A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, Pique JM, Panes J. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000; 80: 1541–1551.[Medline] [Order article via Infotrieve]
36. Sonenshein GE. Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol. 1997; 8: 113–119.[CrossRef][Medline] [Order article via Infotrieve]
37. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995; 376: 167–170.[CrossRef][Medline] [Order article via Infotrieve]
38. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 1999; 18: 6910–6924.[CrossRef][Medline] [Order article via Infotrieve]
39. Birkey RS, Wurthner JU, Parks WT, Roberts AB, Duckett CS. X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-ß signaling. J Biol Chem. 2001; 276: 26452–26459.
40. Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, Ueno N, Nishida E, Shibuya H, Matsumoto K. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 1999; 18: 179–187.[CrossRef][Medline] [Order article via Infotrieve]
41. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994; 93: 2578–2583.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				C. Savoia, R. M. Touyz, F. Amiri, and E. L. Schiffrin Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients Hypertension, February 1, 2008; 51(2): 432 - 439. [Abstract] [Full Text] [PDF]

				K. Sachidanandam, V. Portik-Dobos, A. K. Harris, J. R. Hutchinson, E. Muller, M. H. Johnson, and A. Ergul Evidence for Vasculoprotective Effects of ETB Receptors in Resistance Artery Remodeling in Diabetes Diabetes, November 1, 2007; 56(11): 2753 - 2758. [Abstract] [Full Text] [PDF]

				S. W. Watts, C. Rondelli, K. Thakali, X. Li, B. Uhal, M. H. Pervaiz, R. E. Watson, and G. D. Fink Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2438 - H2448. [Abstract] [Full Text] [PDF]

				S. Wong, F. E. Brennan, M. J. Young, P. J. Fuller, and T. J. Cole A Direct Effect of Aldosterone on Endothelin-1 Gene Expression in Vivo Endocrinology, April 1, 2007; 148(4): 1511 - 1517. [Abstract] [Full Text] [PDF]

				J. L. Wright, H. Tai, R. Wang, X. Wang, and A. Churg Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-{alpha} signaling Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L125 - L133. [Abstract] [Full Text] [PDF]

				S. Jesmin, Y. Hattori, S. Maeda, S. Zaedi, I. Sakuma, and T. Miyauchi Subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by normalization of upregulated endothelin system in rats Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2146 - H2154. [Abstract] [Full Text] [PDF]

				E. L. Schiffrin Effects of Aldosterone on the Vasculature Hypertension, March 1, 2006; 47(3): 312 - 318. [Full Text] [PDF]

				A. Vidal, Y. Sun, S. K. Bhattacharya, R. A. Ahokas, I. C. Gerling, and K. T. Weber Calcium paradox of aldosteronism and the role of the parathyroid glands Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H286 - H294. [Abstract] [Full Text] [PDF]

				A. Fenning, G. Harrison, R. Rose'meyer, A. Hoey, and L. Brown L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1408 - H1416. [Abstract] [Full Text] [PDF]

				A. K. Harris, J. R. Hutchinson, K. Sachidanandam, M. H. Johnson, A. M. Dorrance, D. W. Stepp, S. C. Fagan, and A. Ergul Type 2 Diabetes Causes Remodeling of Cerebrovasculature via Differential Regulation of Matrix Metalloproteinases and Collagen Synthesis: Role of Endothelin-1 Diabetes, September 1, 2005; 54(9): 2638 - 2644. [Abstract] [Full Text] [PDF]

				L. Brown Cardiac extracellular matrix: a dynamic entity Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H973 - H974. [Full Text] [PDF]

				J. Rodriguez-Vita, M. Ruiz-Ortega, M. Ruperez, V. Esteban, E. Sanchez-Lopez, J. J. Plaza, and J. Egido Endothelin-1, via ETA Receptor and Independently of Transforming Growth Factor-{beta}, Increases the Connective Tissue Growth Factor in Vascular Smooth Muscle Cells Circ. Res., July 22, 2005; 97(2): 125 - 134. [Abstract] [Full Text] [PDF]

				A. Csiszar, K. E. Smith, A. Koller, G. Kaley, J. G. Edwards, and Z. Ungvari Regulation of Bone Morphogenetic Protein-2 Expression in Endothelial Cells: Role of Nuclear Factor-{kappa}B Activation by Tumor Necrosis Factor-{alpha}, H2O2, and High Intravascular Pressure Circulation, May 10, 2005; 111(18): 2364 - 2372. [Abstract] [Full Text] [PDF]

				D. M. Pollock Endothelin, Angiotensin, and Oxidative Stress in Hypertension Hypertension, April 1, 2005; 45(4): 477 - 480. [Full Text] [PDF]

				R. Morishita Is Vascular Endothelial Growth Factor a Missing Link Between Hypertension and Inflammation? Hypertension, September 1, 2004; 44(3): 253 - 254. [Full Text] [PDF]

				E. L. Schiffrin and R. M. Touyz From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H435 - H446. [Full Text] [PDF]

				D Schuppan and T Freitag Fistulising Crohn's disease: MMPs gone awry Gut, May 1, 2004; 53(5): 622 - 624. [Full Text]

				E. L. Schiffrin The Many Targets of Aldosterone Hypertension, May 1, 2004; 43(5): 938 - 940. [Full Text] [PDF]

B. G. Petrich, B. C. Eloff, D. L. Lerner, A. Kovacs, J. E. Saffitz, D. S. Rosenbaum, and Y. Wang Targeted Activation of c-Jun N-terminal Kinase in Vivo Induces Restrictive Cardiomyopathy and Conduction Defects J. Biol. Chem., April 9, 2004; 279(15): 15330 - 15338. [Abstract] [Full Text]